Ten year age- and sex-specific temporal trends in incidence and prevalence of heart failure in Västra Götaland, Sweden.


Journal

ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191

Informations de publication

Date de publication:
12 2022
Historique:
revised: 02 07 2022
received: 03 04 2022
accepted: 28 07 2022
pubmed: 13 8 2022
medline: 24 12 2022
entrez: 12 8 2022
Statut: ppublish

Résumé

Heart failure (HF) is predominantly a disorder of the elderly. During the last decades, cardiovascular primary and secondary prevention and life expectancy have improved. Accordingly, trends in incidence and prevalence of HF are dynamic and may differ over time by age and gender. We aim to investigate the overall and age-specific and sex-specific trends, in incidence, prevalence, and the proportion with co-morbidities of HF over a 10 year period in Region Västra Götaland, Sweden. The VEGA database is an administrative database of all patients managed in hospital and/or in primary care (private and public) living in Region Västra Götaland. All patients with a main or contributory diagnosis of HF (I50) aged 18 years or older between 2008 and 2017 were included. Incidence and prevalence of HF were calculated based on the entire adult population of Region Västra Götaland. The adult population in Region Västra Götaland increased by 8% from 2008 (n = 1 234 609) to 2017 (n = 1 338 906). Half the population was female and 69% < 60 years of age, both constant over time. In total, 62 228 incident cases of HF were identified. In 2008, we identified 6464 cases, mean age 78.7 (11.5) years, and 49.8% (n = 3222) men, while in 2017, 5727 cases were identified, mean age 78.3 (11.8) years, and 52.5% (n = 3006) men. The overall yearly incidence rate of HF decreased by 3%, RR 0.97 (95% CI 0.96-0.97) per year, P < 0.0001, mainly driven by the age categories >75 years. A constantly higher incidence of HF was seen for men compared with women in all age categories, RR 1.46 (95% CI 1.44-1.49), P < 0.0001. During the same period, we observed a steady increase in overall prevalence from 1.8% for women and 2.0% for men in 2008, to 2.4% in women and 2.8% in men in 2017, particularly in those >85 years of age who had a prevalence of 16.5% (men) and 14.6% (women) in 2008 and 23.5% (men) and 21.5% (women) in 2017. The overall 1 year mortality rate was 22.7%. When adjusted for age, women had a lower risk for death by 13% compared with men [hazard ratio 0.87 (95% CI 0.84-0.90, P < 0.0001)]. We saw a decrease in overall incidence, but incidence of HF remains high, particularly in the oldest age groups. Prevalence of HF keeps increasing particularly in those aged >85 years. Our findings emphasize the need for implementation of effective preventive strategies for HF.

Identifiants

pubmed: 35957620
doi: 10.1002/ehf2.14103
pmc: PMC9773728
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3931-3941

Informations de copyright

© 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Références

Circulation. 2015 Jun 23;131(25):2176-84
pubmed: 25910800
Eur Heart J. 2004 Sep;25(18):1614-9
pubmed: 15351160
Eur Heart J. 2017 Jun 21;38(24):1926-1933
pubmed: 27311731
Eur J Heart Fail. 2011 Jan;13(1):18-28
pubmed: 20685685
Heart. 2021 Feb;107(3):201-207
pubmed: 32820014
JAMA. 2004 Jul 21;292(3):344-50
pubmed: 15265849
ESC Heart Fail. 2022 Dec;9(6):3931-3941
pubmed: 35957620
JAMA. 2000 Mar 8;283(10):1295-302
pubmed: 10714728
BMC Public Health. 2011 Jun 09;11:450
pubmed: 21658213
Lancet. 2018 Feb 10;391(10120):572-580
pubmed: 29174292
Eur J Heart Fail. 2011 Feb;13(2):135-41
pubmed: 21118860
Circ Heart Fail. 2010 Mar;3(2):236-43
pubmed: 20071655
N Engl J Med. 2002 Oct 31;347(18):1397-402
pubmed: 12409541
N Engl J Med. 2010 Oct 21;363(17):1597-607
pubmed: 20961243
Scand J Prim Health Care. 2005 Dec;23(4):227-32
pubmed: 16272071
Eur Heart J. 2014 Jan;35(1):25-32
pubmed: 23900697
N Engl J Med. 1987 Jun 4;316(23):1429-35
pubmed: 2883575
BMJ. 2012 Jan 25;344:d8059
pubmed: 22279113
Eur J Heart Fail. 2005 Aug;7(5):787-91
pubmed: 15916919
Circulation. 2018 Dec 11;138(24):2774-2786
pubmed: 29950404
Eur J Heart Fail. 2002 Aug;4(4):531-9
pubmed: 12167394
ESC Heart Fail. 2020 Feb;7(1):36-45
pubmed: 31869528
Eur Heart J. 2008 Feb;29(3):339-47
pubmed: 18156618
Eur J Heart Fail. 2013 Sep;15(9):995-1002
pubmed: 23645498
Eur J Heart Fail. 2014 Jul;16(7):737-42
pubmed: 24863749
Heart. 2007 Sep;93(9):1137-46
pubmed: 17699180
Eur Heart J. 2009 Mar;30(6):671-8
pubmed: 19109351
Eur J Heart Fail. 2001 Jun;3(3):283-91
pubmed: 11377998
N Engl J Med. 2014 Sep 11;371(11):993-1004
pubmed: 25176015

Auteurs

Maria Wideqvist (M)

Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Annika Rosengren (A)

Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Medicine, Geriatrics and Emergency Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.

Maria Schaufelberger (M)

Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Medicine, Geriatrics and Emergency Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.

Aldina Pivodic (A)

Statistiska konsultgruppen, Gothenburg, Sweden.
Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Michael Fu (M)

Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Medicine, Geriatrics and Emergency Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH